RGEN

REPLIGEN CORP

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 730272Held by 6 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

6 managers · Q2 2026 13F

13F bookWeight

12 West Capital Management

12 West Capital ManagementPosition history →

7.1%

+46.5%

$38.2M

$0.53B13F book · 2026-06-30

Maverick Capital

Lee AinsliePosition history →

2.4%

+30.7%

$270.8M

$11.08B13F book · 2026-06-30

Holocene Advisors

Holocene AdvisorsPosition history →

0.40%

+82.3%

$176.3M

$43.69B13F book · 2026-06-30

Weitz Investment Management

Wallace WeitzPosition history →

0.39%

+60.0%

$5.6M

$1.44B13F book · 2026-06-30

Duquesne Family Office

Stanley DruckenmillerPosition history →

0.24%

NEW

$10.6M

$4.35B13F book · 2026-06-30

Royce & Associates

Royce & AssociatesPosition history →

0.19%

+50.8%

$23.8M

$12.42B13F book · 2026-06-30

Weight = position value ÷ the manager's total 13F long-equity value in the same filing — one definition for every row. “1st obs.” marks a position with no earlier stored 13F to compare against — it is not shown as a purchase.